Press Releases Items Per Page 102550 News Category FinancialGeneral Year None202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Therapeutics Presents Clinical Data for NKTR-255 in Patients with Relapsed/Refractory Hematologic Malignancies, Including Patients with Prior CAR-T Therapy, at the 63rd American Society of Hematology (ASH) Annual Meeting Dec 13, 2021 Nektar Therapeutics Announces Data Presentations for its Immuno-Oncology Programs at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) Congress 2021 and the 63rd American Society of Hematology (ASH) Annual Meeting Nov 30, 2021 Nektar Therapeutics Strengthens Board of Directors with Appointment of Diana M. Brainard, M.D. Nov 15, 2021 Nektar Therapeutics Announces Data Presentations for Its Immuno-Oncology Pipeline at the 2021 Society for Immunotherapy of Cancer (SITC) Annual Meeting Nov 12, 2021 Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors with Cancer Specialist During 2021 Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Nov 09, 2021 Nektar Therapeutics Reports Third Quarter 2021 Financial Results Nov 04, 2021 Nektar to Announce Financial Results for the Third Quarter 2021 on Thursday, November 4, 2021, After Close of U.S.-Based Financial Markets Oct 26, 2021 Nektar Announces New Clinical Collaboration with Merck KGaA Darmstadt, Germany and Pfizer Inc. to Combine NKTR-255, a Novel Interleukin-15 Agonist, with Avelumab in the JAVELIN Bladder Medley Study Sep 21, 2021 Nektar Therapeutics Reports Second Quarter 2021 Financial Results Aug 05, 2021 Nektar to Announce Financial Results for the Second Quarter 2021 on Thursday, August 5, 2021, After Close of U.S.-Based Financial Markets Jul 27, 2021 Pagination First page « first Previous page ‹ previous Page 1 Page 2 Page 3 Page 4 Current page 5 Page 6 Page 7 Page 8 Page 9 … Next page next › Last page last »